Galenika Building Facility for Production of Modern Medicine Liraglutide for Type 2 Diabetes

The pharmaceutical company Galenika ad Beograd has filed the request for deciding on the necessity of the environmental impact assessment of the project of the reconstruction of a part of the existing facility into a factory for the production of peptide-based injection products.

The new facility for the production of the active pharmaceutical ingredient (API) the liraglutide peptide, a modern medicine used in treating type 2 diabetes, will be located next to the existing facility.

The reconstruction of the existing facility for the production of injection products will adapt it to the needs of the new technology, says the preliminary design for the project, prepared by FormaPharm Engineering Group from Belgrade.

Pilot doses of 200 grams of the peptide liraglutide will be produced at the new facility.

– The production of a commercial dose (2 kg of the peptide liraglutide) is planned in the future, for which an additional space is planned, necessary to accommodate equipment of a larger capacity – the project says and adds that product quality control will be done externally, in an accredited laboratory.

B. P.

Galenika a.d. Beograd

Ministarstvo zaštite životne sredine Republike Srbije

FormaPharm Engineering Group

Galenika ad Zemun

FormaPharm Engineering Group Belgrade

liraglutide

production of medicines for type 2 diabetes

modern medicines for type 2 diabetes

pilot project